8-K: Coya Therapeutics Reports Q3 Results, Advances ALS & FTD Programs

Coya Therapeutics announced its third quarter 2025 financial results, highlighting progress in its neurodegenerative disorder pipeline and an extended cash runway.

Summary

• Coya Therapeutics reported a net loss of $2.1 million for the three months ended September 30, 2025, an improvement from a $4.0 million net loss in the same period of 2024.
• Collaboration revenues for Q3 2025 were $3.6 million, primarily due to the immediate recognition of $3.3 million in license revenue upon receiving FDA acceptance of the IND for the Phase 2 Study.
• Cash and cash equivalents totaled $28.1 million as of September 30, 2025.
• The company completed an upsized public offering of common stock, raising $23.0 million, which is anticipated to extend its cash runway into the second half of 2027.
• The FDA accepted the Investigational New Drug (IND) application for COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
• Coya received a $4.2 million milestone payment from strategic partner Dr. Reddy's Laboratories for the achievement of IND approval.
• The ALSTARS Trial, a Phase 2 clinical study to assess the efficacy and safety of COYA 302 in ALS, was launched and accepted by NEALS as an affiliated trial.
• Preclinical in-vivo animal study results for COYA 303 (LD IL-2 and GLP-1RA) demonstrated promising Central Nervous System (CNS) anti-inflammatory effects and systemic regulatory T cell (Treg) enhancing effects.
• Patient enrollment was completed in an investigator-initiated, open-label study evaluating low-dose IL-2 and CTLA4-Ig combination treatment in patients with mild to moderate Frontotemporal Dementia (FTD).

Sentiment

Score: 8

Explanation: The company reported a reduced net loss, significant collaboration revenue, successful capital raise extending cash runway, and major clinical advancements including FDA IND acceptance and Phase 2 trial launch for COYA 302 in ALS. These are strong positive indicators for a clinical-stage biotech.

Positives

• Net loss significantly improved to $2.1 million in Q3 2025 from $4.0 million in Q3 2024.
• Generated $3.6 million in collaboration revenues in Q3 2025, including a $3.3 million license revenue from IND acceptance.
• Successfully closed a $23.0 million public offering, extending cash runway into 2H 2027.
• FDA accepted the Investigational New Drug (IND) application for COYA 302 for ALS.
• Received a $4.2 million milestone payment from Dr. Reddy's Laboratories for IND approval.
• Launched the ALSTARS Trial, a Phase 2 clinical study for COYA 302 in ALS, which was accepted as a NEALS-affiliated trial.
• Preclinical data for COYA 303 demonstrated promising CNS anti-inflammatory and systemic regulatory T cell (Treg) enhancing effects.
• Completed patient enrollment in an investigator-initiated study for Frontotemporal Dementia (FTD).

Negatives

• Research and development (R&D) expenses increased to $2.9 million in Q3 2025 from $2.2 million in Q3 2024, driven by clinical advancement and internal R&D.
• General and administrative expenses increased to $2.6 million in Q3 2025 from $2.2 million in Q3 2024, due to increased employee compensation and public filing/listing costs.
• Cash and cash equivalents decreased from $38.3 million at December 31, 2024, to $28.1 million at September 30, 2025, prior to the recent capital raise.
• The company continues to operate at a net loss, despite the improvement.

Risks

• Risks associated with the impact of COVID-19.
• The success, cost, and timing of product candidate development activities and ongoing and planned clinical trials.
• The ability to obtain and maintain regulatory approval for product candidates.
• The potential therapeutic benefits and economic value of product candidates.
• The ability to obtain funding for operations.
• The timing of and ability to obtain and maintain intellectual property protection.
• Dependence on third-party manufacturers.
• The success of competing therapies or products that are or may become available.
• The ability to attract and retain key scientific or management personnel.
• The ability to identify additional product candidates with significant commercial potential consistent with commercial objectives.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.

Future Outlook

Coya Therapeutics anticipates enrolling and dosing the first patient in the COYA 302 ALSTARS Trial in the coming weeks, which is expected to trigger another $4.2 million milestone payment from strategic partner Dr. Reddy's Laboratories. The company also expects to present comprehensive in-vivo animal data for COYA 303, publish longitudinal ALS biomarker data, report additional single cell proteomics data from an Alzheimer's disease study, and release top-line clinical data for an investigator-initiated trial in FTD. An IND submission for FTD is anticipated in Q4 2025, with a subsequent Phase 2 trial expected to commence following FDA approval. The recent financing extends the cash runway into the second half of 2027, past the ALSTARS topline readout.

Management Comments

• "We believe the Company's recent financing, which included participation from both new biotech and healthcare institutional investors and existing investors is a testament to their confidence in our programs; we greatly appreciate their support." Arun Swaminathan, Ph.D., Chief Executive Officer.
• "With this financing we anticipate extending our runway into 2H 2027 and past the ALSTARS topline readout." Arun Swaminathan, Ph.D., Chief Executive Officer.
• "With the start of the ALSTARS phase 2 trial, and as up to 25 research sites are initiated, we expect enrollment to begin and for patients to be dosed in the coming weeks." Dr. Fred Grossman, Chief Medical Officer.
• "We also look forward to the data analysis from the IIT in patients with FTD. We then expect to be submitting an IND to study COYA 302 in a phase 2 trial in patients with FTD and begin the study following approval by the FDA of the IND." Dr. Fred Grossman, Chief Medical Officer.

Industry Context

Coya Therapeutics operates in the highly competitive and rapidly evolving biotechnology sector, specifically targeting neurodegenerative disorders like ALS and FTD. The company's focus on regulatory T cell (Treg) function represents a distinct immunomodulatory approach within the industry, differentiating it from traditional symptomatic treatments. Successful IND acceptance and progression to Phase 2 trials for COYA 302 in ALS, along with promising preclinical data for COYA 303, position Coya as a player advancing novel biologic therapies in areas with significant unmet medical needs. The strategic partnership with Dr. Reddy's Laboratories provides external validation and financial support, which is common in early-stage biotech development.

Comparison to Industry Standards

• The company's focus on Treg-enhancing biologics for neurodegenerative disorders like ALS and FTD places it in a niche but competitive field. For ALS, current FDA-approved treatments like Riluzole and Edaravone offer modest benefits, setting a low bar for new therapies to demonstrate improved efficacy.
• The receipt of a $4.2 million milestone payment from Dr. Reddy's Laboratories upon IND acceptance for COYA 302 is a positive indicator of external validation and a common practice in biotech partnerships, comparable to similar early-stage development deals seen with larger pharmaceutical companies partnering with smaller biotechs for pipeline assets.
• Extending the cash runway into 2H 2027 through a $23.0 million public offering is a significant achievement for a clinical-stage biotech, providing stability for ongoing trials. This runway is crucial given the high capital requirements and long development timelines typical for CNS drug development, where many companies struggle with financing beyond early-stage trials.
• The ALSTARS trial for COYA 302 in ALS, being a Phase 2 randomized, multi-center, double-blind, placebo-controlled study, aligns with standard rigorous clinical trial designs for demonstrating efficacy and safety in neurodegenerative diseases. Its acceptance as a NEALS-affiliated trial suggests a level of scientific rigor and collaboration within the ALS research community.
• Preclinical data for COYA 303 showing CNS anti-inflammatory effects and systemic Treg enhancement is promising, but direct comparisons to other preclinical candidates are difficult without specific data points. However, the focus on both systemic and CNS inflammation is a recognized strategy in neuroinflammation research, similar to approaches taken by companies like Denali Therapeutics or Alector in targeting neuroinflammatory pathways.

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway, reduced net loss, and significant clinical progress, potentially increasing long-term value.
• Patients (ALS/FTD): Potential for new therapeutic options with the advancement of COYA 302 into Phase 2 trials.
• Employees: Continued stability and progress in clinical programs may foster a positive work environment and job security.
• Strategic Partner (Dr. Reddy's Laboratories): Continued collaboration and milestone payments indicate a healthy partnership.

Next Steps

• First patient enrolled in COYA 302 ALSTARS Trial.
• First patient dosed in COYA 302 ALSTARS Trial.
• Receive $4.2 million milestone payment from Dr. Reddy's Laboratories upon first patient dosing of COYA 302 in ALS.
• Presentation and publication of comprehensive in-vivo animal data set of COYA 303 (LD IL-2 + CTLA-4 Ig) and its impact on systemic and brain inflammation.
• Publication of longitudinal data on Neurofilament Light Chain (NfL) and oxidative stress markers in patients with ALS (ALS Biomarker data).
• Report additional single cell proteomics data from the completed investigator-initiated, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD).
• Release top-line clinical data for an investigator-initiated trial combining LD IL-2 + CTLA4-Ig in patients with FTD.
• IND submission for FTD anticipated in Q4 2025.
• Begin Phase 2 study for COYA 302 in FTD following FDA approval of the IND.

Key Dates

Recommendation

The company has demonstrated significant progress in its clinical pipeline with FDA IND acceptance for COYA 302 in ALS and the launch of a Phase 2 trial, along with promising preclinical data for COYA 303. The substantial reduction in net loss and the generation of collaboration revenue indicate improving financial health. Crucially, the successful $23.0 million public offering has extended the cash runway into 2H 2027, providing critical funding stability for ongoing and upcoming clinical milestones, including another expected milestone payment. These developments de-risk the company's near-term operations and enhance its long-term potential in addressing high-unmet-need neurodegenerative diseases, making it an attractive investment for growth-oriented investors.

Keywords

Coya Therapeutics, COYA, Biotechnology, Neurodegenerative Disorders, ALS, Frontotemporal Dementia, FTD, Parkinson's Disease, Regulatory T Cells, Tregs, COYA 302, COYA 303, Clinical Trials, Phase 2, IND, FDA, Financial Results, Q3 2025, Cash Runway, Public Offering, Dr. Reddy's Laboratories